Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Urine Test

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44380   clinical trials with a EudraCT protocol, of which   7392   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    6,391 result(s) found for: Urine Test. Displaying page 115 of 320.
    «« First « Previous 111  112  113  114  115  116  117  118  119  Next» Last»»
    EudraCT Number: 2008-006778-14 Sponsor Protocol Number: BT-CL-PGG-LCA0822 Start Date*: 2009-03-06
    Sponsor Name:Biothera
    Full Title: A Phase 2, Randomized, Efficacy and Safety Study of Imprime PGG® Injection in Combination with Cetuximab and Concomitant Paclitaxel and Carboplatin Therapy in Patients with Previously Untreated Adv...
    Medical condition: Patients with Previously Untreated Advanced (Stage IIIB or IV) Non-Small Cell Lung Cancer
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029522 Non-small cell lung cancer stage IV PT
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029521 Non-small cell lung cancer stage IIIB PT
    14.1 10022891 - Investigations 10061773 Coagulation factor VIII level abnormal PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2013-003905-24 Sponsor Protocol Number: AP311736 Start Date*: 2014-02-12
    Sponsor Name:SFJ Pharma Ltd. II
    Full Title: ADJUVANT AXITINIB TREATMENT OF RENAL CANCER: A RANDOMIZED DOUBLE-BLIND PHASE 3 STUDY OF ADJUVANT AXITINIB VS. PLACEBO IN SUBJECTS AT HIGH RISK OF RECURRENT RCC
    Medical condition: Renal Cell Carcinoma
    Disease: Version SOC Term Classification Code Term Level
    16.1 100000004864 10038415 Renal cell carcinoma stage unspecified LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2017-004805-42 Sponsor Protocol Number: SB-FIX-1501 Start Date*: 2018-06-05
    Sponsor Name:Sangamo Therapeutics, Inc.
    Full Title: A Phase I, Open-Label, Ascending Dose Study to Assess the Safety and Tolerability of AAV2/6 Factor IX Gene Therapy via Zinc Finger Nuclease (ZFN) mediated targeted integration of SB-FIX in Subjects...
    Medical condition: Severe Haemophilia B
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004850 10018939 Haemophilia B (Factor IX) LLT
    Population Age: Adolescents, Under 18, Adults Gender: Male
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2008-005964-15 Sponsor Protocol Number: IMCL CP12-0715 Start Date*: 2010-01-08
    Sponsor Name:IMCLONE LLC
    Full Title: A Phase 3, Randomized, Double-Blinded Study of IMC-1121B and Best Supportive Care (BSC) Versus Placebo and BSC in the Treatment of Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Fol...
    Medical condition: Metastatic Gastric Cancer
    Disease: Version SOC Term Classification Code Term Level
    12.1 10066354 Adenocarcinoma of the gastroesophageal junction LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed) ES (Completed) CZ (Completed) MT (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2008-006212-38 Sponsor Protocol Number: 20080580 Start Date*: 2009-07-06
    Sponsor Name:Amgen Inc
    Full Title: Phase 2, Open-label Single-Arm, Multi-Center Study to Evaluate the Efficacy and Safety of AMG 386 and Sorafenib as First Line Therapy for Subjects with Advanced or Inoperable Hepatocellular Carcinoma.
    Medical condition: advanced or inoperable hepatocellular carcinoma
    Disease: Version SOC Term Classification Code Term Level
    9.1 10019828 Hepatocellular carcinoma non-resectable LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2006-004380-58 Sponsor Protocol Number: A3711045 Start Date*: 2007-03-15
    Sponsor Name:Pfizer Limited
    Full Title: A MULTI-CENTER, RANDOMIZED, CROSS-OVER, DOUBLE-BLIND, THIRD PARTY OPEN, PLACEBO CONTROLLED, PILOT STUDY TO ASSESS THE URODYNAMIC EFFECTS OF MODIFIED RELEASE UK-369,003 IN MEN WITH LOWER URINARY TRA...
    Medical condition: Lower Urinary Tract Symptoms
    Disease: Version SOC Term Classification Code Term Level
    8.1 10024981 Lower urinary tract infection LLT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: NL (Completed) CZ (Completed) LV (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2018-002282-19 Sponsor Protocol Number: ΕΑΕ-2018/ΜΜ03 Start Date*: 2018-09-28
    Sponsor Name:Hellenic Society of Hematology
    Full Title: A Phase 2, Multicenter, Open-label, Single-Arm Study to Evaluate the Safety and Efficacy of Daratumumab in Combination with Ixazomib and Dexamethasone as Second Line Therapy in Multiple Myeloma Pat...
    Medical condition: Relapsed and /or Refractory Multiple Myeloma
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10028228 Multiple myeloma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2018-004014-17 Sponsor Protocol Number: ALN-GO1-004 Start Date*: 2019-03-01
    Sponsor Name:Alnylam Pharmaceuticals, Inc.
    Full Title: ILLUMINATE-B: An Open-Label Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Lumasiran in Infants and Young Children with Primary Hyperoxaluria Type 1
    Medical condition: Primary Hyperoxaluria Type 1 (PH1)
    Disease: Version SOC Term Classification Code Term Level
    20.1 10038359 - Renal and urinary disorders 10020703 Hyperoxaluria PT
    Population Age: Newborns, Infants and toddlers, Children, Under 18 Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) FR (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2021-001498-21 Sponsor Protocol Number: A011-14 Start Date*: 2021-11-11
    Sponsor Name:Acceleron Pharma Inc.
    Full Title: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Sotatercept When Added to Maximum Tolerated Background Therapy in Participants With Pulmonary Arterial Hypertension (PAH) W...
    Medical condition: Pulmonary Arterial Hypertension (PAH)
    Disease: Version SOC Term Classification Code Term Level
    21.1 10038738 - Respiratory, thoracic and mediastinal disorders 10064911 Pulmonary arterial hypertension PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing) IT (Trial now transitioned) NL (Trial now transitioned) BE (Trial now transitioned) DE (Trial now transitioned) FR (Trial now transitioned)
    Trial results: View results
    EudraCT Number: 2018-000805-22 Sponsor Protocol Number: A2017SCI03 Start Date*: 2019-06-11
    Sponsor Name:Neuroplast BV
    Full Title: A multi-center, double-blind, randomized, placebo-controlled, delayed-start phase II/III study to assess the efficacy and safety of Neuro-Cells in (sub)acute spinal cord injury patients.
    Medical condition: Traumatic spinal cord injury
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: DK (Completed) ES (Ongoing)
    Trial results: View results
    EudraCT Number: 2006-000781-37 Sponsor Protocol Number: NKV102549 Start Date*: 2006-07-24
    Sponsor Name:GlaxoSmithKline Research and Development Ltd
    Full Title: A Phase III, Multicenter, Randomized, Double-Blind, Active Controlled, Parallel Group Study of the Safety and Efficacy of the Intravenous and Oral Formulations of the Neurokinin-1 Receptor Antagon...
    Medical condition: Chemotherapy induced nausea and vomiting (CINV) due to Moderately Emetogenic Chemotherapy (MEC)
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) DE (Completed) BE (Completed) IE (Completed) SK (Completed) ES (Completed) AT (Completed) EE (Completed) CZ (Completed) LT (Completed) HU (Completed) DK (Completed) LV (Completed) GR (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2019-002992-33 Sponsor Protocol Number: 54135419TRD3013 Start Date*: 2020-08-04
    Sponsor Name:Janssen-Cilag International NV
    Full Title: A Randomized, Open-label, Rater-Blinded, Active-Controlled, International, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of Flexibly Dosed Esketamine Nasal Spray Compared Wit...
    Medical condition: Treatment-Resistant Major Depressive Disorder
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004873 10081270 Major depressive disorder LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed) CZ (Completed) PL (Completed) DE (Completed) HU (Completed) FR (Completed) BE (Completed) PT (Completed) BG (Completed) DK (Completed) AT (Completed) NO (Completed) FI (Completed) GR (Completed)
    Trial results: View results
    EudraCT Number: 2019-003076-39 Sponsor Protocol Number: ARGX-113-1802 Start Date*: 2020-06-25
    Sponsor Name:argenx BVBA
    Full Title: A Phase 2 Trial to Investigate the Efficacy, Safety, and Tolerability of Efgartigimod PH20 SC in Adult Patients With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
    Medical condition: Chronic Inflammatory Demyelinating Polyneuropathy
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004852 10077384 Chronic inflammatory demyelinating polyneuropathy LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) PL (Completed) HU (Completed) ES (Completed) LV (Completed) CZ (Completed) GB (GB - no longer in EU/EEA) BE (Completed) NL (Completed) BG (Completed) DK (Completed) AT (Completed) IT (Completed) RO (Completed)
    Trial results: View results
    EudraCT Number: 2019-003444-72 Sponsor Protocol Number: MK-6482-005 Start Date*: 2020-02-17
    Sponsor Name:Merck Sharp & Dohme LLC
    Full Title: An Open-label, Randomized Phase 3 Study of MK-6482 Versus Everolimus in Participants with Advanced Renal Cell Carcinoma That Has Progressed After Prior PD- 1/L1 and VEGF-Targeted Therapies
    Medical condition: Advanced Renal Cell Carcinoma
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10067946 Renal cell carcinoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FI (Trial now transitioned) NO (Trial now transitioned) HU (Trial now transitioned) DE (Trial now transitioned) FR (Trial now transitioned) DK (Trial now transitioned) ES (Ongoing) GB (GB - no longer in EU/EEA) SE (Trial now transitioned) IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2006-005270-47 Sponsor Protocol Number: 309363 Start Date*: 2007-04-23
    Sponsor Name:Schering AG
    Full Title: International, multicenter, Phase IIIb study of subcutaneous every-other-day treatment of patients with relapsing multiple sclerosis with (Phase A) double-blind Betaseron/Betaferon 250 µg or 500 µg...
    Medical condition: relapsing multiple sclerosis
    Disease: Version SOC Term Classification Code Term Level
    9.1 10028245 Multiple sclerosis LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: FI (Completed) BE (Completed) IE (Completed) FR (Completed) AT (Completed) SE (Completed) ES (Completed) DE (Completed) HU (Completed) LV (Completed) SI (Completed) NL (Completed) GR (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2006-004139-31 Sponsor Protocol Number: M06-810 Start Date*: 2007-04-03
    Sponsor Name:Abbott GmbH & Co. KG
    Full Title: A Multicenter, Randomized, Double-Period, Double − Blind Study to Determine the Optimal Protocol for Treatment Initiation with Methotrexate and Adalimumab Combination Therapy in Patients with Early...
    Medical condition: Rheumatoid Arthritis.
    Disease: Version SOC Term Classification Code Term Level
    8.1 10039073 Rheumatoid arthritis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) GB (Completed) SK (Completed) ES (Completed) AT (Completed) FR (Completed) SE (Completed) CZ (Completed) DE (Completed) NL (Completed) HU (Completed) NO (Completed) GR (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2021-005034-42 Sponsor Protocol Number: MK-7684A-008 Start Date*: 2022-01-31
    Sponsor Name:Merck Sharp & Dohme LLC
    Full Title: A Phase 3, Randomized, Double-Blind Study of MK-7684A in Combination with Etoposide and Platinum Followed by MK-7684A vs Atezolizumab in Combination with Etoposide and Platinum Followed by Atezoliz...
    Medical condition: Extensive-stage small-cell lung cancer
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10041068 Small cell lung cancer extensive stage PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Trial now transitioned) ES (Ongoing) FI (Trial now transitioned) HU (Trial now transitioned) IT (Trial now transitioned) LT (Trial now transitioned) IE (Trial now transitioned) PL (Trial now transitioned) FR (Trial now transitioned) AT (Trial now transitioned) NL (Trial now transitioned) PT (Trial now transitioned) GR (Trial now transitioned) RO (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2016-004935-18 Sponsor Protocol Number: GNC-004 Start Date*: 2017-04-12
    Sponsor Name:GeNeuro SA
    Full Title: A Long-Term International, Extension of Study GNC-003, with GNbAC1 in Patients with Relapsing Remitting Multiple Sclerosis
    Medical condition: Multiple Sclerosis (MS)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029205 - Nervous system disorders 10063399 Relapsing-remitting multiple sclerosis PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: HU (Completed) DE (Prematurely Ended) CZ (Prematurely Ended) ES (Prematurely Ended) PL (Prematurely Ended) BG (Prematurely Ended) HR (Prematurely Ended) IT (Completed)
    Trial results: View results
    EudraCT Number: 2007-003572-19 Sponsor Protocol Number: V00114 CP 302 2A Start Date*: 2007-12-04
    Sponsor Name:Pierre Fabre Médicament
    Full Title: EFFICACY AND SAFETY STUDY OF THE ANTIHISTAMINE V0114CP 2.5MG IN THE TREATMENT OF PERENNIAL ALLERGIC RHINITIS. RANDOMISED, DOUBLE-BLIND, THREE ARM PARALLEL GROUP STUDY INCLUDING PLACEBO AND ACTIV...
    Medical condition: The intended indication for the product under development is the treatment of perennial allergic rhinitis.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: EE (Prematurely Ended) LT (Prematurely Ended) CZ (Completed) GB (Prematurely Ended) ES (Completed) FI (Prematurely Ended) LV (Completed) AT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2016-002146-23 Sponsor Protocol Number: ASN100-201 Start Date*: 2017-01-19
    Sponsor Name:Arsanis, Inc.
    Full Title: A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Determine the Safety and Efficacy of a Single Dose of ASN100 for the Prevention of Staphylococcus aureus Pneumonia in Heavily Coloni...
    Medical condition: Prevention of Staphylococcus aureus Pneumonia in Heavily Colonized, Mechanically Ventilated Subjects
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Prematurely Ended) CZ (Completed) DE (Prematurely Ended) ES (Completed) PT (Prematurely Ended) AT (Prematurely Ended) PL (Prematurely Ended) IT (Prematurely Ended) RO (Prematurely Ended)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    «« First « Previous 111  112  113  114  115  116  117  118  119  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Thu Feb 12 00:00:24 CET 2026 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA